China and US Equity Analyst

Roger Xie

Equity Bottom-Up

<ul style="list-style-type: disc;">
<li>
<a href="https://www.smartkarma.com/entities/hong-kong-exchanges-clearing" target="_blank" data-smartkarma-citation="entities:490:1" rel="noopener">HKEX (388 HK)</a> December ADT (Average Daily Turnover) re-accelerated strongly, delivering amazing 86% year-over-year growth in the month. The outperformance is helped by the rising global equity markets and strong IPO listings in Hong Kong. For the year 2020, HKEx ADT has accelerated the year-over-year growth rate to 49%, which is one the best trading volume years recently. In 2020, HKEx stock price rose 68%, outperforming Hang Seng Index down 3%. We believe HKEx momentum will continue in 2021.</li>
<li>We maintain our sanguine view on trading activities and IPO pipeline in Hong Kong market in 2021. <a href="https://www.smartkarma.com/entities/hong-kong-exchanges-clearing" target="_blank" data-smartkarma-citation="entities:490:1" rel="noopener">HKEX (388 HK)</a> will benefit from this secular trend in several ways: 1) Hong Kong market becomes de facto choice for China new economy companies for IPO and fund raising; 2) HKEx Northbound trading has become an increasing important factor as the gateway to invest in China A-share; 3) MSCI index products will continue to gain market share. We forecast Securities ADT of HK$240bn in FY 21 (Hong Kong and Stock Connect Northbound) and raise HKEx TP HKD 500. </li>
<li>HKEx announced that Calvin Tai Chi Kin has replaced Charles Li Xiaojia as its new interim Chief Executive, effective from 1st January 2021. Calvin Tai Chi Kin, a financial industry veteran, has been named HKEx' Interim CEO since last September. He will take over Charles Li Xiaojia’s responsibilities and continue his role as Co-President and Chief Operating Officer of HKEx. <p>Calvin brings a wealth of experience of more than thirty-five years to his new position. According to the media, several candidates have been considered by HKEx, but the final decision on HKEx CEO has not been reached. </p>
</li>
</ul>



HKEX (388 HK) December ADT (Average Daily Turnover) re-accelerated strongly, delivering amazing 86% year-over-year growth in the month. The outperformance is helped by the rising global equity markets and strong IPO listings in Hong Kong. For the year 2020, HKEx ADT has accelerated the year-over-year growth rate to 49%, which is one the best trading volume years recently. In 2020, HKEx stock price rose 68%, outperforming Hang Seng Index down 3%. We believe HKEx momentum will continue in 2021.
We maintain our sanguine view on trading activities and IPO pipeline in Hong Kong market in 2021. HKEX (388 HK) will benefit from this secular trend in several ways: 1) Hong Kong market becomes de facto choice for China new economy companies for IPO and fund raising; 2) HKEx Northbound trading has become an increasing important factor as the gateway to invest in China A-share; 3) MSCI index products will continue to gain market share. We forecast Securities ADT of HK$240bn in FY 21 (Hong Kong and Stock Connect Northbound) and raise HKEx TP HKD 500. 
HKEx announced that Calvin Tai Chi Kin has replaced Charles Li Xiaojia as its new interim Chief Executive, effective from 1st January 2021. Calvin Tai Chi Kin, a financial industry veteran, has been named HKEx' Interim CEO since last September. He will take over Charles Li Xiaojia’s responsibilities and continue his role as Co-President and Chief Operating Officer of HKEx. Calvin brings a wealth of experience of more than thirty-five years to his new position. According to the media, several candidates have been considered by HKEx, but the final decision on HKEx CEO has not been reached. 



HKEx (388.HK): A Blockbuster Year 2020; Becoming Regional Leader in Years Ahead; Raise TP to HK$500

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

<div><p><a href="https://www.smartkarma.com/entities/yidu-tech-inc" target="_blank" data-smartkarma-citation="entities:29245:1" rel="noopener">Yidu Tech Inc (2158 HK)</a> is a software company that offers healthcare solutions built on big data and artificial intelligence (AI) technologies. Yidu ranked No.1 in terms of revenue among all healthcare big data solution providers in China in 2019 with a market share of 5.0% in the healthcare big data solutions market in China, according to EY.  Yidu Tech will commence trading on Friday, 15 January. Yidu Tech priced its IPO at HK$26.30 and <a href="https://www.thestandard.com.hk/section-news/section/2/226552/US%243b-Bilibili-IPO-to-open-in-March" target="_blank" rel="noopener">opened 154% higher</a> at HK$67.00 in the grey market.</p></div><div><p>In <a href="https://www.smartkarma.com/insights/yidu-tech-ipo-initiation-patient-revolution" target="_blank" data-smartkarma-citation="insights:46392" rel="noopener">Yidu Tech IPO Initiation: Patient Revolution</a>, we stated that Yidu is an attractive play on China’s healthcare industry rising spend on IT and data services. In <a href="https://www.smartkarma.com/insights/yidu-tech-ipo-valuation-insights" target="_blank" data-smartkarma-citation="insights:46734" rel="noopener">Yidu Tech IPO: Valuation Insights</a>, we noted that the IPO price range is attractive.</p></div><div><div><div class="content-highlight"><p>Our base-case DCF derived price target of HK$40.06 per share, 52% above the IPO price. As DCF-based target prices are subject to a wide range of variability, we present a sensitivity table to help investors gauge where target prices could head. Our DCF sensitivity analysis shows that the IPO price continues to provide good upside potential. </p></div></div></div>

Yidu Tech Inc (2158 HK) is a software company that offers healthcare solutions built on big data and artificial intelligence (AI) technologies. Yidu ranked No.1 in terms of revenue among all healthcare big data solution providers in China in 2019 with a market share of 5.0% in the healthcare big data solutions market in China, according to EY.  Yidu Tech will commence trading on Friday, 15 January. Yidu Tech priced its IPO at HK$26.30 and opened 154% higher at HK$67.00 in the grey market.In Yidu Tech IPO Initiation: Patient Revolution, we stated that Yidu is an attractive play on China’s healthcare industry rising spend on IT and data services. In Yidu Tech IPO: Valuation Insights, we noted that the IPO price range is attractive.Our base-case DCF derived price target of HK$40.06 per share, 52% above the IPO price. As DCF-based target prices are subject to a wide range of variability, we present a sensitivity table to help investors gauge where target prices could head. Our DCF sensitivity analysis shows that the IPO price continues to provide good upside potential. 

APAC IPOs & Placements

Zhen Zhou, Toh

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

<p><a href="https://www.smartkarma.com/entities/yidu-tech-inc" target="_blank" data-smartkarma-citation="entities:29245:1" rel="noopener">Yidu Tech Inc (2158 HK)</a> (Yidu) raised about US$539m in its Hong Kong IPO after pricing at HK$26.30 per share, the top-end of the price range.</p>
<div>
<p>Yidu is a healthcare data solution provider. It leverages big data and artificial intelligence (AI) technologies and provides solutions to key healthcare participants that include mainly hospitals, pharmaceutical, biotech and medical device companies, regulators and policy makers. </p>
</div>
<div>
<p>Our previous coverage of the IPO:</p>
</div>
<div>
<ul style="list-style-type: disc;">
<li>
<a href="https://www.smartkarma.com/insights/yidu-tech-pre-ipo-big-buzzwords" target="_blank" data-smartkarma-citation="insights:46381" rel="noopener">Yidu Tech (医渡云) Pre-IPO - Big Buzzwords</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/yidu-tech-pre-ipo-forecast-and-peer-valuation" target="_blank" data-smartkarma-citation="insights:46462" rel="noopener">Yidu Tech (医渡云) Pre-IPO - Forecast and Peer Valuation</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/yidu-tech-ipo-expensive-but-it-s-still-justifiable" target="_blank" data-smartkarma-citation="insights:46707" rel="noopener">Yidu Tech (医渡云) IPO - Expensive but It's Still Justifiable</a> </li>
</ul>
</div>

Yidu Tech Inc (2158 HK) (Yidu) raised about US$539m in its Hong Kong IPO after pricing at HK$26.30 per share, the top-end of the price range.

Yidu is a healthcare data solution provider. It leverages big data and artificial intelligence (AI) technologies and provides solutions to key healthcare participants that include mainly hospitals, pharmaceutical, biotech and medical device companies, regulators and policy makers. 


Our previous coverage of the IPO:




Yidu Tech (医渡云) Pre-IPO - Big Buzzwords 

Yidu Tech (医渡云) Pre-IPO - Forecast and Peer Valuation 

Yidu Tech (医渡云) IPO - Expensive but It's Still Justifiable 



Yidu Tech (医渡云) IPO Trading - Strong Demand Points to Good Debut

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

Alibaba Group Holding  / Equity Capital Markets

<p>2020 marked our second full year of operations as an Independent Research Company, and our fifth year covering Equity Capital Markets (ECM). While the year started off on a precarious note for ECM, it ended with very strong momentum. Even as IPOs have hogged the limelight in 2020, we actually ended up covering more than twice the number of placements as IPOs. </p><p>We ended 2020 with an accuracy rate of 72.7% across 88 IPOs that we covered and 70.1% across 174 placements. While our placements hit rate improved, our IPO hit rate took a dip from 2019.</p><p>For those not familiar with our coverage, we aim to cover all IPOs and placements with a minimum deal size of US$100m across Asia-Pacific (ex-Korea), including China ADRs.</p>

2020 marked our second full year of operations as an Independent Research Company, and our fifth year covering Equity Capital Markets (ECM). While the year started off on a precarious note for ECM, it ended with very strong momentum. Even as IPOs have hogged the limelight in 2020, we actually ended up covering more than twice the number of placements as IPOs. We ended 2020 with an accuracy rate of 72.7% across 88 IPOs that we covered and 70.1% across 174 placements. While our placements hit rate improved, our IPO hit rate took a dip from 2019.For those not familiar with our coverage, we aim to cover all IPOs and placements with a minimum deal size of US$100m across Asia-Pacific (ex-Korea), including China ADRs.

Aequitas 2020 IPOs and Placements Performance - IPOs in the Limelight but Placements Stole the Show

Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

Equity Analyst

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

<p>The big data and AI solutions provider for healthcare sector in China, <a href="https://www.smartkarma.com/entities/yidu-tech-inc" target="_blank" data-smartkarma-citation="entities:29245:1" rel="noopener">Yidu Tech Inc (2158 HK)</a>  has set the terms for its IPO. The company was ranked no. 1 in terms of revenue among all healthcare big data solution providers in China in 2019.</p><p>China is the world’s second largest healthcare market, and the country has been increasingly informatizing the healthcare system in order to improve the efficiency as well as close the huge healthcare resource gap to meet emerging demands for high quality holistic health management.</p><p>The company plans to issue 156.5m shares at an indicative IPO price range of HK$23.5-26.5 per share, and at the midpoint of the IPO price range of HK$24.90 per share, Yidu Tech will raise gross proceeds of US$503m (HK$3.9bn).</p><p>In our previous insights on the company’s IPO, we examined the company’s business model, segments, revenues and profitability. In this insight, we examine the company’s valuation.</p>

The big data and AI solutions provider for healthcare sector in China, Yidu Tech Inc (2158 HK)  has set the terms for its IPO. The company was ranked no. 1 in terms of revenue among all healthcare big data solution providers in China in 2019.China is the world’s second largest healthcare market, and the country has been increasingly informatizing the healthcare system in order to improve the efficiency as well as close the huge healthcare resource gap to meet emerging demands for high quality holistic health management.The company plans to issue 156.5m shares at an indicative IPO price range of HK$23.5-26.5 per share, and at the midpoint of the IPO price range of HK$24.90 per share, Yidu Tech will raise gross proceeds of US$503m (HK$3.9bn).In our previous insights on the company’s IPO, we examined the company’s business model, segments, revenues and profitability. In this insight, we examine the company’s valuation.

Yidu Tech IPO Valuation: Attractive at the Low-End but Superior Growth Profile Justifies the Premium

China

JD Health International Inc. operates drug stores. The Company retails Chinese and Western medicines, nutrition products, health care products, and other products. JD Health International markets its products throughout China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

JD Health International (6618 HK)

HKEx (388.HK): A Blockbuster Year 2020; Becoming Regional Leader in Years Ahead; Raise TP to HK$500

We maintain our sanguine view on trading activities and IPO pipeline in Hong Kong market in 2021and raise HKEx TP HKD 500.

Roger Xie

Yidu Tech IPO: Trading Debut

Yidu Tech priced its IPO at HK$26.30 and opened 154% higher at HK$67.00 in the grey market. Our DCF sensitivity analysis shows that the IPO price...

Arun George

Yidu Tech (医渡云) IPO Trading - Strong Demand Points to Good Debut

Yidu Tech Inc (2158 HK) (Yidu) raised about US$539m in its Hong Kong IPO after pricing at HK$26.30 per share, the top-end of the price range.

Zhen Zhou, Toh

Aequitas 2020 IPOs and Placements Performance - IPOs in the Limelight but Placements Stole the Show

2020 marked our second year of operations as an Independent Research Company, and our fifth year covering ECM. In 2020 we had an accuracy rate of...

Sumeet Singh

Yidu Tech IPO Valuation: Attractive at the Low-End but Superior Growth Profile Justifies the Premium

The big data and AI solutions provider for healthcare sector in China, Yidu Tech has set the terms for its IPO and in this insight, we examine Yidu...

Shifara Samsudeen, ACMA, CGMA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)